https://scholars.lib.ntu.edu.tw/handle/123456789/525132
標題: | Pompe disease: Early diagnosis and early treatment make a difference | 作者: | YIN-HSIU CHIEN WUH-LIANG HWU NI-CHUNG LEE |
公開日期: | 2013 | 卷: | 54 | 期: | 4 | 起(迄)頁: | 219-227 | 來源出版物: | Pediatrics and Neonatology | 摘要: | Pompe disease (glycogen storage disease type II or acid maltase deficiency) is a lysosomal disorder in which acid α-glucosidase (GAA) deficiencies lead to intralysosomal accumulation of glycogen in all tissues; most notably in skeletal muscles. Both the patient's age at the onset of Pompe disease symptoms and the rate of deterioration caused by the disease can vary considerably. In classical infant-onset Pompe disease (IOPD), symptoms start very early in life, and death occurs soon afterward if the disease remains untreated. In later-onset Pompe disease, symptoms are slower to appear, and patients often progress to wheelchair confinement and eventual respiratory failure. A diagnosis can be made by screening for GAA in dried blood samples, followed either by GAA assessment in lymphocytes or in fibroblasts or by the genetic analysis of mutations. Treatment by enzyme replacement therapy (ERT) with alglucosidase alfa was approved for human use in 2006. In classical IOPD, treatment significantly lengthens survival and improves motor development and cardiac function. The sooner ERT begins, the better are the results. Newborn screening aims to take advantage of different technologies for diagnosing and treating newborns early on and it yields better outcomes. However, newborns diagnosed early and other long-term survivors may encounter fresh problems, making up a new phenotype of IOPD patients. Further modifications of the treatment, such as a decrease in immune responses to ERT, a higher dosage, a better uptake formulation, and gene therapy delivered locally or systemically are being explored. ? 2012, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84880823455&doi=10.1016%2fj.pedneo.2013.03.009&partnerID=40&md5=5563ad14dce1918c8f78034bb883b6d7 https://scholars.lib.ntu.edu.tw/handle/123456789/525132 |
ISSN: | 1875-9572 | DOI: | 10.1016/j.pedneo.2013.03.009 | SDG/關鍵字: | agalsidase beta; imiglucerase; laronidase; recombinant glucan 1,4 alpha glucosidase; velaglucerase alfa; artificial ventilation; chromosome 17q; disease classification; early diagnosis; enzyme replacement; exon; Fabry disease; food and drug administration; Gaucher disease; gene frequency; gene therapy; glycogen storage disease type 2; human; Hurler syndrome; immune response; intron; laboratory diagnosis; long term survival; molecular weight; mucopolysaccharidosis; newborn disease; newborn screening; phase 3 clinical trial (topic); phenotype; predictive value; respiratory failure; review; acid α-glucosidase; enzyme replacement therapy; glycogen storage disease type II; newborn screening; Pompe disease; Age Factors; alpha-Glucosidases; Child, Preschool; Early Diagnosis; Echocardiography, Doppler; Enzyme Replacement Therapy; Female; Genetic Therapy; Glycogen Storage Disease Type II; Humans; Infant; Infant, Newborn; Male; Neonatal Screening; Prognosis; Risk Assessment; Survival Rate; Treatment Outcome |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。